Risk factor
Moderate default risk
Profitability factor
Greatly undervalued vs peers
About
Medios AG, along with its affiliated entities, operates in Germany as a wholesaler specializing in niche pharmaceutical products. The company structures its operations into two main areas: Pharmaceutical Supply and Patient-Specific Therapies. The Pharmaceutical Supply division provides a diverse range of products aimed at conditions within oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia. Conversely, the Patient-Specific Therapies segment focuses on creating bespoke medications for individual patients, frequently on behalf of pharmacies, and also prepares personalized treatments that involve precisely dosed tablets. Medios AG was founded in 2016 and maintains its corporate headquarters in Berlin, Germany.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is fairly valued on P/E, undervalued on EV
Target Price
The average target price of ILM1.DE is 22 and suggests 86% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre